G lucose homeostasis is dysregulated in critically ill patients, resulting in the development of hyperglycemia, irrespective of previously diagnosed diabetes. Peripheral insulin resistance develops in these patients, which is reflected by the combined picture of higher levels of insulin, elevated hepatic glucose production, and impaired peripheral glucose uptake (1) . This condition has been labeled stress diabetes or diabetes of injury (2, 3) .
Until recently, it was considered state of the art to tolerate blood glucose levels up to 12.2 mmol/L (220 mg/dL) in fed critically ill patients (4) , and only excessive hyperglycemia exceeding this value was treated. Above this threshold, hyperglycemia-induced osmotic diuresis and fluid shifts occur and uncontrolled and pronounced hyperglycemia predisposes to infectious complications, as known from the diabetes literature (3, 5) . Arguments to tolerate glucose levels up to 12.2 mmol/L were the classic dogma that moderate hyperglycemia in critically ill patients is beneficial for organs that largely rely on glucose for energy supply but do not require insulin for glucose uptake, such as the brain and blood cells, and the fear for occasional hypoglycemia and subsequent brain injury with tight glucose management.
Stress hyperglycemia had long been considered an adaptive and beneficial response. The recent Leuven large, randomized clinical trials, one on surgical (6) and one on medical (7) critical illness, argued against this concept by showing that maintenance of normoglycemia with intensive insulin therapy to a large extent prevents morbidity and reduces mortality of critically ill patients. However, several concerns have been raised with regard to the efficacy and safety of this intervention. In this review, we give an overview of how hyperglycemia affects the outcome of critically ill patients and how survival and morbidity can be improved by strict blood glucose control with intensive insulin therapy, and we discuss the existing controversies and how they can be refuted or justified by the available evidence.
HYPERGLYCEMIA AND RISK OF ADVERSE OUTCOME OF CRITICALLY ILL PATIENTS
Several recent studies clearly identify the development of hyperglycemia as an important risk factor in terms of mortality and morbidity of critically ill patients. In patients undergoing cardiac surgery, hyperglycemia has been associated with a substantial mortality risk and delayed extubation (8, 9) . Intraoperative hyperglycemia seemed to be an independent risk factor for adverse outcome after cardiac surgery (10) . Also, hyperglycemia was associated with an increased risk of death in patients with myocardial infarction and also in patients with risk of congestive heart failure and cardiogenic shock (11) . Elevated glucose levels predicted increased mortality and length of intensive care unit (ICU) and hospital stay of trauma patients and were associated with infectious morbidity and prolonged need of mechanical ventilation (12) (13) (14) (15) . Apart from the predictive value of hyperglycemia for worse survival of patients with severe brain injury, a significant relationship was found between high blood glucose levels and worse neurologic status, impaired pupil reactivity, intracranial hypertension, and longer hospital length of stay (16, 17) . Similarly, hyperglycemia predicted a higher risk of death after stroke and a poor functional recovery in those patients who survived (18) . In addition, a strong link has been described between increased blood glucose levels and the risk of critical illness polyneuropathy in sepsis and the systemic inflammatory response syndrome (19) . Also, in critically ill children, hyperglycemia develops and is associated with worse outcome (20) . Particularly in severely burned children, mortality, incidence of bacteremia and fungemia, and number of skin grafting procedures were higher in hyperglycemic patients (21) . Retrospective analysis of a heterogeneous population of critically ill patients revealed that even a modest degree of hyperglycemia was associated with substantially increased hospital mortality (22) . In addition, variability in glucose levels during critical illness has been related to mortality (23) .
STRICT BLOOD GLUCOSE CONTROL WITH INTENSIVE INSULIN THERAPY IN CRITICAL ILLNESS: EVIDENCE FROM THE LEUVEN PROSPECTIVE, RANDOMIZED STUDIES
The first strong evidence against the traditional concept of tolerating glucose levels as high as 11.1 mmol/L (200 mg/ dL) came from the landmark prospective, randomized, controlled study on intensive insulin therapy in adult surgical critically ill patients (6) . Recently, the clinical benefits of this therapy were largely confirmed in a large, randomized, controlled trial in a strictly medical adult ICU patient population (7).
Intensive Insulin Therapy in the Surgical ICU
A large group of patients admitted to the ICU predominantly after extensive, complicated surgery or trauma, or after medical complications of major surgical procedures, were included in this study (6) . In the conventional approach, patients received insulin only if glucose concentrations exceeded 11.9 mmol/L (215 mg/dL). Mean blood glucose levels were 8.8 mmol/L (158 mg/dL, hyperglycemia). Insulin was administered to the patients in the intensive insulin therapy group to maintain blood glucose levels between 4.4 and 6.1 mmol/L (80 -110 mg/dL), which resulted in mean blood glucose levels of 5.4 mmol/L (98 mg/dL, normoglycemia). Tight blood glucose control with insulin strikingly lowered ICU mortality from 8.0% to 4.6% (absolute risk reduction [ARR] of 3.4%) and in-hospital mortality from 10.9% to 7.2% (ARR of 3.7%) ( Table 1 , Fig. 1 ). The benefit increased with the duration of insulin therapy, with a 9.6% absolute ICU mortality reduction (from 20.2% to 10.6%) and a 9.5% in-hospital mortality reduction (from 26.3% to 16.8%) ( Fig. 1 ).
Besides saving lives, intensive insulin therapy largely prevented several critical illness-associated complications. The incidence of critical illness polyneuropathy, bloodstream infections, acute renal failure, hyperbilirubinemia, and anemia was reduced. Patients were also less dependent on prolonged mechanical ventilation and intensive care. The prevention of critical illness polyneuropathy explained the lower risk of prolonged mechanical ventilation (24) . Particularly in the group of patients with isolated brain injury, intensive insulin therapy protected the central and peripheral nervous system from secondary insults and improved longterm rehabilitation (24) . Finally, a recent post hoc healthcare resource utilization analysis also revealed economic advantages of intensive insulin therapy, with substantial cost savings compared with conventional insulin therapy in this surgical patient population (25) . For the subgroup of patients who were included in the study after complicated cardiac surgery, a follow-up study showed that intensive insulin therapy also improved long-term outcome, when given for at least a third day in the ICU, with maintenance of the survival benefit up to 4 yrs after randomization (26) . Risk for hospital re-admission and dependency on medical care were similar in both groups. The short-term glycemic control with insulin during intensive care did not induce a substantial burden for the patients, their relatives, or society, but the perceived quality of social and family life seemed to be moderately compromised.
Intensive Insulin Therapy in the Medical ICU
Following the same insulin-titration protocol as in the surgical study, glycemia was controlled to mean levels of 5.8 mmol/L (105 mg/dL) in the intensive insulin therapy group, as compared with 8.9 mmol/L (160 mg/dL) in the conventional glucose management (7). In the target group of long-stay patients needing at least a third day of intensive care, for which the study had been powered based on the results of the surgical study, tight glycemic control with insulin significantly reduced in-hospital mortality from 52.5% to 43.0% (ARR of 9.5%) ( Fig. 1) . A nonsignificant reduction in in-hospital mortality from 40.0% to 37.3% (ARR of 2.7%) ( Fig. 1) was observed for the intention-to-treat population of 1,200 patients. The lack of statistical significance was not a surprise, as the study was not powered for this mortality end point. This would require inclusion of Ն5,000 patients.
Morbidity was significantly reduced in the intention-to-treat group of patients receiving intensive insulin therapy. New development of kidney injury occurred less frequently, the therapy allowed earlier weaning from mechanical ventilation and earlier discharge from the ICU and from the hospital, and the patients less frequently developed hyperbilirubinemia. The reduction in morbidity was even more striking in the target group of patients remaining in the ICU for at least a third day. These patients were discharged from the hospital alive, on average, 10 days earlier than those receiving conventional insulin therapy. In contrast to the surgical patients, there was no difference in bacteremia or prolonged antibiotic therapy requirement, but the number of long-stay patients with hyperinflammation was also reduced. In the patients who needed intensive care for Ն7 days, intensive insulin therapy reduced the incidence of critical illness polyneuropathy or myopathy, which partially explained the lower dependency on mechanical ventilatory support for Ͼ14 days (27) .
CRITICISM AND CONCERNS WITH REGARD TO INTENSIVE INSULIN THERAPY
The Leuven studies showed clinical benefit of intensive insulin therapy. However, concerns have been raised about the fact that they both were single-center studies and that some other studies yielded apparently conflicting results. Also, concerns remain regarding confounding factors, optimal level of blood glucose control, and potential harm.
What Do We Learn from Other Studies on Insulin Therapy in Critical Illness?
Several decades ago, the infusion of glucose together with insulin and potassium (GIK) emerged as a metabolic cocktail to reduce early mortality and morbidity of patients with acute myocardial infarction and yielded promising results. However, two recent large, randomized trials on GIK therapy in patients with acute myocardial infarction (CREATE- (28, 29) . In the CREATE-ECLA study, mortality and the incidence of cardiac arrest, cardiogenic shock, and reinfarction were all comparable for patients who received GIK and those who did not (28) . However, no simultaneous glucose control was performed, and GIK therapy even increased glucose levels compared with the usual care. The DIGAMI-2 trial (29) was set up to investigate whether the clinical benefit of the first DIGAMI study (30 -32) was mediated by an acute effect of GIK and that of blood glucose control during the months after the infarction. No significant effect was seen on mortality, and also, morbidity, evaluated by the occurrence of nonfatal reinfarctions and strokes, was not affected (29) . Importantly, the target of normal glucose levels assigned to one of the groups was not reached. This excludes an acute effect of GIK in the absence of blood glucose control, but no conclusion can be drawn with respect to the effect of blood glucose control because of unintended protocol violation. Likewise, GIK infusion for 24 hrs after acute stroke failed to realize a significant reduction in glycemia or mortality, as examined in the Glucose-Insulin in Stroke Trial (GIST) (33) .
The prospective, randomized, multicenter VISEP (volume substitution and insulin therapy in severe sepsis) trial was designed as a four-arm study to assess the choice of fluid resuscitation and the efficacy and safety of intensive insulin therapy in patients with severe sepsis and septic shock, using mortality and organ dysfunction as outcome variables (34) . The insulin arm of the study was stopped prematurely because the rate of hypoglycemia in the intensive treatment group (12.1%) was considered unacceptably high. Among the included patients (n ϭ 488), 90-day mortality was 29.5% in the intensive vs. 32.8% in the conventional treatment arm (ARR of 3.3%) (35) . This difference was not statistically significant, however, as only 488 patients (moreover, divided over four treatment arms and 17 centers) had been included. Hence, the study is totally underpowered to draw conclusions on the efficacy and safety of intensive insulin therapy in this patient population.
The GLUCONTROL study was set up as a prospective, randomized, controlled, multicenter trial to investigate whether tight glycemic control to 4.4 -6.1 mmol/L (80 -110 mg/dL) with insulin vs. 7.8 -10.0 mmol/L (140 -180 mg/dL) improves survival in a mixed population of critically ill patients, with in-hospital and 28-day mortality, length of ICU and hospital stay, length of ICU stay without life-support therapy, number and clinical signs of hypoglycemic episodes, incidence of infection and organ failure, and number of red cell transfusions as secondary outcome variables (36). However, the steering committee and the data safety monitoring board decided to stop the enrollment of patients after the first interim analysis because the target glycemic control was
Recruitment of patients in the NICE-SUGAR (Normoglycemia in Intensive Care Evaluation and Survival Using Glucose Algorithm Regulation) study, another multicenter, randomized clinical trial on the effects of blood glucose management of intensive care patients, is still ongoing (37) . The results are awaited with great interest.
In "real-life" intensive care of a heterogeneous medical/surgical patient population, an observational study had evaluated the effect of implementing a tight glucose management protocol, by comparison with historical controls as a reference (38) , and largely confirmed the clinical benefits of this intervention. Intravenous insulin was administered only if glucose levels exceeded 11.1 mmol/L (200 mg/dL) on two successive measurements and aimed to lower glycemia to Ͻ7.8 mmol/L (140 mg/dL). Hence, blood glucose control was somewhat less strict than in the Leuven studies and resulted in mean glucose levels of 7.3 mmol/L (131 mg/dL) in the protocol period, compared with 8.4 mmol/L (152 mg/dL) in the baseline period. In comparison with the historical control group, the implementation of the glucose control protocol resulted in a 6.1% ARR for hospital mortality (from 20.9% to 14.8%), length of ICU stay decreased, fewer patients developed new renal failure, and fewer patients required red blood cell transfusion. No effect was seen on the occurrence of severe infections, but this complication was not frequently present in the baseline period. The intervention also reduced medical costs (39) .
Another prospective, randomized, controlled study in a predominantly general surgical patient population confirmed the findings of a decreased incidence of total nosocomial infections with intensive insulin therapy targeting glucose levels between 4.4 and 6.7 mmol/L (80 -120 mg/dL) (40) . This intervention resulted in mean daily glucose levels of 6.9 mmol/L (125 mg/ dL) vs. 9.9 mmol/L (179 mg/dL) in the standard glycemic control group.
The CREATE-ECLA, DIGAMI-2, GIST, VISEP, and GLUCONTROL studies are often used to argue against the efficacy of intensive insulin therapy (28, 29, 33, 34, 36) . What they teach us, however, is that insulin therapy without glucose control does not work and that adequate power calculation is of crucial importance to generate conclusive results on reproducibility of the therapy. Appropriate statistical tools for power calculation are easily accessible (41), but they have to be used correctly.
Does Intensive Insulin Therapy Antagonize the Deleterious Effects of Parenteral Nutrition?
Guidelines were followed with regard to feeding of the patients in the Leuven studies (6, 7, 42) , aiming at a total of 22-30 kcal·kg
, with balanced composition of glucose, protein, and lipids. Enteral feeding was attempted as soon as possible when the patients were hemodynamically stable. Parenteral feeding was given early to compensate if the caloric target could not be reached. However, criticism is raised that with this regimen the patients are overfed, unlike the approach adopted in other centers, and that intensive insulin therapy may serve, in part, to offset some of the risk associated with "excessive" parenteral glucose. Nevertheless, analysis of the pooled data set of the two Leuven studies argues against this concept. Indeed, the benefit of intensive insulin therapy was independent of parenteral glucose load, as mortality was lowered in the lowest and the highest tertile of parenteral glucose load in the intention-to-treat population and all tertiles in the patients who needed intensive care for Ն3 days, with the most pronounced benefit detected in the tertile of patients who received the smallest amount of parenteral feeding (43) .
Which Patients Benefit from Intensive Insulin Therapy?
Doubt arose about the efficacy and safety of insulin therapy in short-stay vs. long-stay patients, as expected length of stay cannot always be predicted, and in diagnostic subgroups of patients. As a novel intervention can only be advocated for patients who are likely to benefit from the therapy, this is an important question.
Outcome Benefit of Intensive Insulin Therapy and Expected Length of ICU Stay. In both Leuven studies, the clinical benefit obtained with intensive insulin therapy was more pronounced when the patients received this therapy for at least a few days (6, 7) . In the surgical ICU study, a survival benefit was present for all patients, according to the intentionto-treat principle, and for the long-stay patients (6) . Although insulin therapy in the medical ICU resulted in a significant mortality reduction for the patients with an ICU stay of Ն3 days (i.e., the target population based on the surgical ICU study and supported by studies on cardiac surgery patients with diabetes (44 -46) ), this study is considered negative by many clinicians because of the absence of a statistically significant effect in the intention-to-treat patient population (7) . However, as indicated, the study was not powered for this mortality end point in the intention-to-treat group. Also, a striking parallelism was observed in the mortality benefit of both studies with time in the ICU (Table 1, Fig. 1 ). Moreover, a statistically significant effect was present in intention-to-treat analysis when correction for well-known baseline risk factors was taken into account (odds ratio for intensive insulin, 0.77; 95% confidence interval, 0.60 -0.99; p ϭ .04). Hence, it seems unjustified to consider the study negative for mortality.
In the medical study, an apparently higher number of short-stay patients in the intensive insulin treatment group died (56 of 209 patients) than short-stay patients in the conventional group (42 of 224 patients), which was of concern to the practicing clinician. However, a post hoc exploratory mortality analysis revealed that this observation is likely explained by selection bias. Indeed, for 36 short-stay patients, intensive care had been limited or withdrawn within 72 hrs after ICU admission for reasons of futility, imbalanced among the conventional (n ϭ 10) and intensive (n ϭ 26) insulin therapy groups. When correcting for the wellknown at-admission risk factors that are the major reasons for therapy restriction, however, mortality was comparable in both groups.
Importantly, when the data sets from the surgical and the medical study were pooled, statistical power was sufficient to show morbidity and mortality effects of intensive insulin therapy in the intention-totreat patient population, with a higher benefit for those who needed intensive care for Ն3 days and without causing harm to patients by brief insulin treatment for Ͻ3 days (43) .
Benefit of Intensive Insulin Therapy in Diagnostic Subgroups of Critically Ill
Patients. Large diagnostic subgroups were identified in the mixed medical/ surgical patient population of the Leuven studies. In most of them, including pa-tients with cardiovascular, respiratory, gastrointestinal/hepatic disease or surgery, sepsis, and active malignancy, intensive insulin therapy reduced mortality and morbidity (43, 47) . The absolute reduction in the risk of death was quite comparable in all of these subgroups. Only in the group of patients with a history of diabetes was no survival benefit observed, but morbidity also tended to be reduced in these patients. In multivariate logistic regression analysis, correcting for other at-admission risk factors, such as severity of illness and cancer, and for intensive insulin therapy in the ICU (odds ratio, 0.78; 95% confidence interval, 0.63-0.96; p ϭ .02), patients with diabetes who had previously been treated with medication other than insulin had a lower risk of death (odds ratio, 0.61; 95% confidence interval, 0.40 -0.93; p ϭ .02), whereas those who were receiving insulin treatment before critical illness had a tendency for an increased risk of death (odds ratio, 1.39; 95% confidence interval, 0.96 -2.01; p ϭ .08). The exact reason for this statistical association remains to be investigated.
What is the Optimal Level of Blood Glucose Control?
A four-arm design study in a rabbit model of critical illness recently showed that blood glucose control mediated the survival benefit of intensive insulin therapy and not a direct effect of insulin (48) . The clinical data are in agreement with this observation. In surgical critically ill patients, the risk of death seemed to be linearly correlated with the degree of hyperglycemia, with no clear cut-off level below which there was no further benefit (49) . The highest risk of death was observed for the conventionally treated patients who developed severe hyperglycemia (8.3-11.1 mmol/L or 150 -200 mg/dL), and an intermediate risk was observed for patients who received conventional insulin therapy and who developed only moderate hyperglycemia (6.1-8.3 mmol/L or 110 -150 mg/dL), whereas the lowest risk was present in the patients whose blood glucose levels were controlled at Ͻ6.1 mmol/L (110 mg/dL) with intensive insulin therapy. This pattern of risk of death in relation to stratification of glycemia was confirmed in the mixed medical/surgical patient population, with most benefit gained when glycemia was controlled at Ͻ6.1 mmol/L (110 mg/dL) (43) . However, in patients with diabetes, risk of death for the three strata of glucose control seemed to mirror this pattern, although no significant differences were noted among these three levels.
Glycemic control also accounted for most effects on morbidity of surgical critical illness (6, 49) . As for mortality, tight glycemic control at Ͻ6.1 mmol/L (110 mg/ dL) seemed to be of crucial importance for the prevention of critical illness polyneuropathy, bacteremia, anemia, and acute renal failure (49) . In particular, a positive linear correlation was observed between glycemia and the risk of developing critical illness polyneuropathy, for which multivariate logistic regression analysis also confirmed the crucial role of preventing glucose toxicity to protect the neurons (24) . Also, in the mixed medical/surgical study, lowering blood glucose levels to Ͻ6.1 mmol/L (110 mg/dL) was most effective to achieve the prevention of newly developed kidney injury and critical illness polyneuropathy (43) .
The above findings underscore the importance of achieving tight glucose control within the target range to obtain the clinical benefits. In the Leuven studies, for 70% of the patients, mean blood glucose levels within the target window of intensive insulin therapy were achieved, whereas for only 3%, 8.3 mmol/L (150 mg/dL) was exceeded. This is in contrast with the 27% of the target reached at the time of interim analysis of the GLUCON-TROL study (36).
Intensive Insulin Therapy and the Risk of Hypoglycemia: Does It Harm the Patient?
The risk of hypoglycemia is a major concern when intensive insulin therapy is administered to critically ill patients because early hypoglycemic symptoms are not easily recognized in these patients (4) and severe hypoglycemia (Ͻ1.7 mmol/L or 30 mg/dL) or prolonged hypoglycemia can lead to convulsions, coma, irreversible brain damage, and cardiac arrhythmias.
The risk of hypoglycemia (glucose of Յ2.2 mmol/L or 40 mg/dL) increased from 0.8% to 5.1% in the surgical (6) and from 3.1% to 18.7% in the medical ICU study (7) when patients received intensive insulin therapy. Susceptibility to the development of hypoglycemia seemed to be particularly high for patients with sepsis (47) . Importantly, these brief episodes of biochemical hypoglycemia were not associated with obvious clinical problems. Indeed, hypoglycemia did not cause early deaths: only minor immediate and transient morbidity was seen in a minority of patients, and no late neurologic sequelae occurred among hospital survivors (43) . Nevertheless, as risk of hypoglycemia coincided with a higher risk of death, equally in both conventional and intensive insulin groups, it cannot be completely excluded that hypoglycemia counteracted some of the survival benefit of intensive insulin therapy. Interestingly, however, a higher mortality was observed with spontaneous hypoglycemia than with hypoglycemic events during insulin infusion. Moreover, in a recent nested-case control study, no causal link was found between hypoglycemia in the ICU and death when case and control subjects were matched for baseline risk factors and time in the ICU before the hypoglycemic event (50) . These observations support the previous suggestion that hypoglycemia in ICU patients who receive intensive insulin therapy may merely identify patients at high risk of dying rather than representing a risk on its own (51) .
As most benefit was gained with the tightest blood glucose control, the risk of hypoglycemia should be weighed against improved outcome. Clearly, the development of accurate blood glucose monitoring in a continuous way and closed-loop systems for computer-assisted blood glucose control in the ICU will help to avoid any eventual side effect that could be induced by hypoglycemia.
High-Dose Insulin Administration to Critically Ill Patients: Could It Be Harmful?
Apart from the risk of hypoglycemia, multivariate logistic regression analysis identified the dose of insulin as a positive risk factor for mortality (6, 49, 52) . This association between high insulin dose and mortality is likely explained by more severe insulin resistance in the sicker patients, who have a high risk of death, but a true deleterious effect of hyperinsulinemia cannot be excluded. However, circulating levels of insulin in patients who received intensive insulin therapy were only transiently higher, despite the large difference in insulin dose administered compared with conventionally treated patients (53) .
MECHANISTIC INSIGHT INTO IMPROVED OUTCOME WITH INTENSIVE INSULIN THERAPY
The blood glucose control or other metabolic effects of insulin that accom-pany tight blood glucose control, and not the insulin dose administered per se, contributed to the improved survival with intensive insulin therapy. Interestingly, hyperglycemia seems to be more acutely toxic in critically ill patients than in healthy individuals or diabetic patients. Studies of critical illness in patients and animal models lead to substantial progress in the understanding of the mechanisms underlying these clinical benefits. A detailed description of these studies is beyond the scope of this review and can be found in other recent overviews (1, 54) . In brief, part of the improvement with intensive insulin therapy is likely explained by preventing glucose toxicity to the mitochondrial compartment (55), the endothelium (48, 56) , the neurons (24) , and immune cells (57) . Other effects of insulin contributing to improved outcome include the partial correction of the abnormal serum lipid profile (58) and the prevention of excessive inflammation (57, 59) . Also, attenuation of the cortisol response to critical illness related to improved outcome with intensive insulin therapy (60) . Considering the mechanism of glucose lowering with intensive insulin therapy, stimulation of glucose uptake by skeletal muscle seems to be important, rather than an effect of insulin on hepatic glucose handling (58, 61) .
CONCLUSIONS
Demonstration of the clinical benefits of intensive insulin therapy seems to depend on the quality of blood glucose control, duration of treatment, and the statistical power of the studies. Indeed, achieving sustained blood glucose control to normoglycemia, while avoiding prolonged hypoglycemia, is of crucial importance to obtain maximal benefit with this therapy. Longstay critically ill patients for whom insulin therapy is continued for Ͼ3 days benefit more, with a higher reduction in the absolute risk of death and in morbidity. Importantly, statistical significance of the outcome benefit can only be reached in studies with sufficient statistical power. This would require the inclusion of Ն5,000 patients to demonstrate an absolute mortality risk reduction of 3-4% in the intention-to-treat patient population, which is anticipated from previous studies.
